About Millennium Pharmaceuticals |
Millennium Pharmaceuticals, Inc., was established in 1993 as a genomics
company applying world-class recombinant technology to the discovery and
development of innovative new therapies in a broad spectrum of diseases.
Millennium has since grown into a fully integrated biopharmaceutical company
with a pipeline of investigational drug candidates, as well as VELCADER
(bortezomib) for Injection, a successfully commercialized medicine derived
from Nobel Prize-winning science that is now approved in more than 87
In May of 2005, the company's leadership changed as Founder Mark Levin
turned the helm over to his carefully selected successor, Deborah Dunsire,
M.D. Although considered remarkably different in management style, Dunsire
embraced the company's culture, and had the skills and experience Levin and
the Board of Directors considered necessary to move the company forward to
greater accountability and sustainable success.
For the next several years, significant refocusing and reconfiguration took
place within Millennium, as well as considerable improvements in the scale
and strength of Commercial Operations.
In May, 2008, Millennium was acquired by Takeda Pharmaceutical Company
Limited. Takeda is the largest pharmaceutical company in Japan, and a global
enterprise with an important presence in key markets.
Millennium now operates as an independent subsidiary, serving as the global
center of excellence in oncology under its new name: "Millennium: The Takeda
Oncology Company." The merger of oncology resources has resulted in a more
robust pipeline of investigational drug candidates.
This new function focuses Millennium efforts on expanding its scope of
responsibility to the global oncology community. Along with an increased
capacity in oncology comes increased accountability for success and a new
mission that puts Millennium on a trajectory toward global oncology
This global footprint includes oncology research and marketing strategy and
oversight. In addition to Cambridge, MA, oncology resources include
facilities in San Diego, San Francisco, Tsukuba and Osaka with Millennium as
the global hub for this critical and rapidly expanding therapeutic area.